Fertility startup Inito has raised $29 million in Series B funding to scale its at-home health diagnostics platform and use AI-designed antibodies to unlock new kinds of at-home tests.
When the company launched its first fertility monitor in 2021, its goal was to make quantitative fertility hormone testing possible at home.
While standard at-home ovulation tests predict fertile days by tracking estrogen and Luteinizing hormone (LH), they don’t measure the hormone that confirms your ovulation, which is progesterone metabolite PdG. Inito…

![[CITYPNG.COM]White Google Play PlayStore Logo – 1500×1500](https://startupnews.fyi/wp-content/uploads/2025/08/CITYPNG.COMWhite-Google-Play-PlayStore-Logo-1500x1500-1-630x630.png)